About Paul Plourde, MD

Paul V. Plourde Paul V. Plourde, MD is the Vice President for Clinical Oncology Development at Sermonix Pharmaceuticals. Prior to Sermonix he was the Senior Vice President of Oncology at AstraZenaca and US head of Phase 2, 3 and 3b trials. Paul has 25 years of experience in developing new oncology medications including the breast cancer drugs tamoxifen, anastrozole, and fulvestrant.

He has 33 years of clinical practice experience in endocrinology and internal medicine and has been involved in 8 regulatory drug approvals.

Paul has affiliations with the American Society of Clinical Oncology as well as the American Society of Hematology and the American Society of Pediatric Oncology and Hematology.

Paul graduated from the University of Maine in 1973 with a BS in Chemical Engineering. He earned an MS in Chemical Engineering in 1974 also from the University of Maine. He completed his academic training at the University of Vermont School of Medicine earning an MD in 1978. He is the author of several scientific publications.

To view the complete CV, please click here.